Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer by William J. Kelly, Neil J. Shah, Deepa S. Subramaniam

Get full text

1237 Long term outcomes of severe endocrine immune-related adverse events (irAEs): adrenal insufficiency (AI) and insulin-dependent diabetes (IDDM) by Andrea Knezevic, Neil J Shah, Ben Nguyen, Monica Girotra

A case of checkpoint inhibitor-induced celiac disease by Dana Alsaadi, Neil J. Shah, Aline Charabaty, Michael B. Atkins

Get full text

Product review on the Anti-PD-L1 antibody atezolizumab by Neil J. Shah, William J. Kelly, Stephen V. Liu, Karin Choquette, Alexander Spira

Get full text

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events by Stephanie L. Gu, Tara Maier, Andrea P. Moy, Stephen Dusza, David M. Faleck, Neil J. Shah, Mario E. Lacouture

Get full text

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade by Jia Luo, Hira Rizvi, Margaret Callahan, Jason Beattie, Paige Fuentes, Adam Schoenfeld, I-Hsin Lin, Neil J Shah, Mohit Chawla

Get full text

1317 Enhancing patient safety in melanoma treatment: harnessing machine learning for predicting immune-related adverse events by Samir Gupta, Michael B Atkins, Neil J Shah, Jacob Zaemes, Shaked Lev Ari, Yili Zhang, Adil Alaoui, Subha Madhavan, Peter McGarvey

Contribution of the Skin–Gut Axis to Immune-Related Adverse Events with Multi-System Involvement by Alyce M. Kuo, Lukas Kraehenbuehl, Stephanie King, Donald Y. M. Leung, Elena Goleva, Andrea P. Moy, Mario E. Lacouture, Neil J. Shah, David M. Faleck

Get full text

Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis by Dongyu Zhang, Neil J. Shah, Michael Cook, Matthew Blackburn, Michael T. Serzan, Shailesh Advani, Arnold L. Potosky, Subha Madhavan, Anas Belouali, Michael B. Atkins, Dejana Braithwaite

Get full text

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era by Neil J. Shah, Sneha D. Sura, Reshma Shinde, Junxin Shi, Puneet K. Singhal, Nicholas J. Robert, Nicholas J. Vogelzang, Rodolfo F. Perini, Robert J. Motzer

Get full text

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors:... by Dongyu Zhang, Neil J. Shah, Michael Cook, Matthew Blackburn, Michael T. Serzan, Shailesh Advani, Arnold L. Potosky, Subha Madhavan, Anas Belouali, Michael B. Atkins, Dejana Braithwaite

Get full text

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection by Neil J. Shah, Ghassan Al-Shbool, Matthew Blackburn, Michael Cook, Anas Belouali, Stephen V. Liu, Subha Madhavan, Aiwu Ruth He, Michael B. Atkins, Geoffrey T. Gibney, Chul Kim

Get full text

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma by Michael B. Atkins, Suthee Rapisuwon, Arash Radfar, Kellie Gardner, Neil J. Shah, Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, David Swoboda, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refaie

Get full text

615 The impact of gender including female menopausal status on the safety and efficacy of immune checkpoint inhibitors by Michael B Atkins, Neil J Shah, Jacob Zaemes, Andrew Pecora, Shaked Lev Ari, Lauren Pascual, Brittany Sinclaire, Alexandra DellaPia, Rachel A Zemel, Adil Alaoui, Andrew Ip, Deniz Ozisik, Ming Tan

1244 Polarized immune responses reveal actionable therapeutic targets in cutaneous adverse events to checkpoint inhibitors by Mario E Lacouture, Neil J Shah, Lukas kraehenbuehl, Stephanie Gu, Andrea P Moy, Elena Goleva, Kwami Ketosugbo, Tara Maier, Trina Salvador, Ryan Weight, Veronica Rotemberg, Jeffrey A Kern, Donald Y Leung

1418 Treatment-free survival in patients with advanced melanoma and non-small cell lung cancer receiving immune checkpoint inhibitors: real-world outcomes over a 3-year timespan by Samir Gupta, Michael B Atkins, Meredith Regan, Neil J Shah, Jacob Zaemes, Opeyemi A Jegede, Shaked Lev Ari, Lauren Pascual, Natali Arias-Orozco, Brittany Sinclaire, Alexandra DellaPia, Rachel A Zemel, Yili Zhang, Adil Alaoui, Andrew Ip

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine by Mariaelena Pierobon, Johann De Bono, Ruth Riisnaes, Giuseppe Giaccone, Matthew Blackburn, Lance Liotta, Vienna Ludovini, Neil J Shah, Giuseppina Improta, Antonella Ravaggi, Niven Mehra, Angelo Sidoni, Elisa Baldelli, K Alex Hodge, Guido Bellezza, Guido Gambara, Martina Mandarano, Chamodya Ruhunusiri, Bryant Dunetz, Maysa Abu-Khalaf, Julia Wulfkuhle, Rosa I Gallagher, Franco Odicino, Maria Isabella Sereni, Angela Zupa, Perry Demsko, Lucio Crino', Emanuel F Petricoin

Get full text

Clinical characterization of colitis arising from anti-PD-1 based therapy by Daniel Y Wang, Meghan J Mooradian, DaeWon Kim, Neil J Shah, Sarah E Fenton, Robert M Conry, Rutika Mehta, Ann W. Silk, Alice Zhou, Margaret L Compton, Rami N Al-Rohil, Sunyoung Lee, Amber L Voorhees, Lisa Ha, Svetlana McKee, Jacqueline T Norrell, Janice Mehnert, Igor Puzanov, Jeffrey A Sosman, Sunandana Chandra, Geoffrey T Gibney, Suthee Rapisuwon, Zeynep Eroglu, Ryan Sullivan, Douglas B Johnson

Get full text